Novartis Focalin ADHD approval
This article was originally published in Pharmaceutical Approvals Monthly
Focalin (dexmethylphenidate), the single-isomer version of Ritalin, is approved Nov. 13 for treatment of attention deficit hyperactivity disorder. The 2.5 mg, 5 mg and 10 mg tablets are expected to be available by the end of January. Novartis had planned to use the tradename Ritadex, but FDA was concerned about prescribing errors due to potential confusion with Ritalin. Novartis acquired worldwide marketing rights to dexmethylphenidate (except in Canada) from Celgene in April 2000
You may also be interested in...
CBER Director Peter Marks said the agency could streamline development by allowing sponsors to depend on an already-approved manufacturing platform and reviewing any modifications that are proposed.
Only 12 US jurisdictions currently have sound COVID-19 virus assays from the Centers for Disease Control and Prevention to test suspected virus cases, CDC director Robert Redfield told a House panel looking at virus preparedness on Wednesday – but a better batch is coming, he said. Other questions raised at the congressional hearing was how long an infected person stays infected, whether COVID-19 can be picked up from inanimate surfaces, and related queries.
Personal-care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3 – Cosmetics and Cleaning Preps.